Aurobindo Pharma Limited has informed the Exchange about Acquisition
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma's step-down subsidiary Agile Pharma BV has created a new wholly owned subsidiary called Arrow Pharma Production SAS in France. The new entity, incorporated on May 21, 2026, will operate in the pharmaceuticals sector focusing on generic formulations manufacturing. The company has subscribed to 100,000 shares at 1 EUR each, totaling an investment of 100,000 EUR in cash. This is a 100% owned subsidiary under the Aurobindo Pharma group structure. No regulatory approvals were required for this incorporation.
This is a routine corporate expansion announcement creating a new manufacturing entity in Europe. The financial outlay is minimal at 100,000 EUR and unlikely to have any material impact on the stock in the short term. Long-term investors may view this as a positive step toward expanding European manufacturing capabilities.